KYTX
Kyverna Therapeutics, Inc. Common Stock
NASDAQ: KYTX · HEALTHCARE · BIOTECHNOLOGY
$9.47
+2.82% today
Updated 2026-05-06
Market cap
$557.48M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.64
Dividend yield
—
52W range
$2 – $14
Volume
0.9M
Kyverna Therapeutics, Inc. Common Stock (KYTX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $5.66M | $7.03M | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | +24.2% | -100.0% | — | — |
| Cost of revenue | $586000.00 | $1.05M | $1.71M | $2.13M | $1.80M |
| Gross profit | $5.66M | $7.03M | $-1.71M | $-2.13M | $-1.80M |
| Gross margin | 100.0% | 100.0% | — | — | — |
| R&D | $25.85M | $28.40M | $48.22M | $112.47M | $133.72M |
| SG&A | $6.15M | $8.01M | $12.48M | $30.13M | $36.11M |
| Operating income | $-26.35M | $-29.38M | $-62.41M | $-142.60M | $-169.83M |
| Operating margin | -465.8% | -418.3% | — | — | — |
| EBITDA | $-25.76M | $-27.78M | $-58.47M | $-125.20M | $-167.38M |
| EBITDA margin | -455.5% | -395.4% | — | — | — |
| EBIT | $-26.35M | $-28.83M | $-60.18M | $-127.33M | $-169.18M |
| Interest expense | $3000.00 | $65000.00 | $187000.00 | $142000.00 | $489000.00 |
| Income tax | $1000.00 | $56000.00 | $132000.00 | $-127.48M | — |
| Effective tax rate | -0.0% | -0.2% | -0.2% | 50.0% | 0.0% |
| Net income | $-26.35M | $-28.89M | $-60.37M | $-127.48M | $-161.31M |
| Net income growth (YoY) | — | -9.7% | -108.9% | -111.2% | -26.5% |
| Profit margin | -465.9% | -411.3% | — | — | — |